Orca Wealth Management LLC Takes $276,000 Position in Johnson & Johnson (NYSE:JNJ)

Orca Wealth Management LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 1,906 shares of the company’s stock, valued at approximately $276,000.

Other hedge funds also recently modified their holdings of the company. Quarry LP bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $49,000. AMF Tjanstepension AB lifted its stake in Johnson & Johnson by 14.2% in the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after acquiring an additional 52,997 shares during the last quarter. Czech National Bank increased its stake in shares of Johnson & Johnson by 6.9% during the 3rd quarter. Czech National Bank now owns 490,381 shares of the company’s stock worth $79,471,000 after purchasing an additional 31,766 shares during the last quarter. Wiser Wealth Management Inc bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at $260,000. Finally, Park Avenue Securities LLC boosted its holdings in Johnson & Johnson by 14.9% in the third quarter. Park Avenue Securities LLC now owns 82,287 shares of the company’s stock worth $13,335,000 after purchasing an additional 10,664 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $152.09 on Friday. The firm has a market capitalization of $366.17 billion, a price-to-earnings ratio of 22.87, a PEG ratio of 2.43 and a beta of 0.51. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The business has a fifty day simple moving average of $147.67 and a 200 day simple moving average of $156.07. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $2.29 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.26%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Analyst Ratings Changes

Several research firms have weighed in on JNJ. Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, January 23rd. Citigroup decreased their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $170.44.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.